As­traZeneca amends li­cense deal with Chi­nese biotech; Chi­nese pro­tein-based vac­cine gets man­u­fac­tur­ing OK

In an ef­fort to boost the sup­ply of its AAV Covid-19 vac­cine abroad, As­traZeneca has amend­ed its li­cense agree­ment with Biokang­tai to com­mer­cial­ize the drug in main­land Chi­na, Pak­istan and In­done­sia, Biokang­tai an­nounced Wednes­day.

Biokang­tai will mar­ket, man­u­fac­ture and dis­trib­ute the drug to ease the short­ened sup­ply and make the vac­cine more ac­ces­si­ble. The vac­cine has been ap­proved in 185 coun­tries so far, the com­pa­ny said in a press re­lease, but short­ened sup­ply, cou­pled with is­sues sur­round­ing rare, but fa­tal, blood clots, have led vac­ci­na­tion num­bers to stall out.

Endpoints News

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters